Publications by authors named "M C Mark"

Background And Objective: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. The CodeBreak 200 trial demonstrated that sotorasib, a new drug targeting the G12C-mutated KRAS protein, modestly improved progression-free survival compared with docetaxel in patients whose cancer had progressed after receiving platinum chemotherapy and programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors as first-line treatment. Consequently, sotorasib received temporary approval in Switzerland.

View Article and Find Full Text PDF

Franco Basaglia's work is the cornerstone of the radical psychiatric movement in Italy. This culminated in the "Basaglia Law" of 1978, which aimed to abolish closed psychiatric institutions. In addition to becoming a symbolic place of movement, Trieste is still trying to preserve and put into practice the Basaglian tradition.

View Article and Find Full Text PDF

Introduction: SCLC is characterized by aggressiveness and limited treatment options, especially in extensive-stage SCLC (ES-SCLC). Immunotherapy added to the platinum-etoposide combination has recently become standard in this setting. This retrospective study aims to evaluate the real-world effectiveness of chemo-immunotherapy in patients with ES-SCLC, focusing on subpopulations excluded from clinical trials.

View Article and Find Full Text PDF

We present the first successful trapping of single erbium atoms in an array of optical tweezers. Using a single narrow-line optical transition, we achieve deep cooling for direct tweezer loading, pairwise ejection, and continuous imaging without additional recoil suppression techniques. Our tweezer wavelength choice enables us to reach the magic trapping condition by tuning the ellipticity of the trapping light.

View Article and Find Full Text PDF
Article Synopsis
  • A study on the combination of ipilimumab (ipi) and nivolumab (nivo) for treating malignant pleural mesothelioma (MPM) in Switzerland revealed real-world survival and safety data, confirming its status as a standard-of-care after positive clinical trial results (CheckMate-743).
  • Among the 109 patients treated from November 2017 to March 2023, the objective response rate to ipi-nivo was 21% for first-line treatment and 15% for second or further-line treatments, with median overall survival being 12.6 months for first-line and 6.9 months for second-line.
  • The treatment was generally well-t
View Article and Find Full Text PDF